Alterity Therapeutics Price Target Announced at $8.00/Share by Maxim Group

Dow JonesDec 12 11:53 ET · Ratings

Alterity Therapeutics Initiated at Buy by Maxim Group

Dow JonesDec 12 11:53 ET · Ratings

Alterity Therapeutics' Vision for Neurodegenerative Care | NYSE:ATHE, ASX:ATH

Proactive InvestorsDec 5 21:43 ET

Press Release: Alterity Therapeutics Appoints Abby Macnish Niven as Chief Financial Officer

Dow JonesSep 30 07:35 ET

Alterity Therapeutics Names New CFO; Shares Down 25%

MT NewswiresSep 29 21:38 ET

Alterity Therapeutics Ltd: Annual Report 2024

ASXSep 25 23:09 ET · Announcements